News | December 30, 2021
Sanofi loses appeal in the US over Lantus device patents
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
Two out of three people under the age of 40 are at risk of prediabetes
This procedure is incidentally the first robotic bariatric surgery in the world to be performed in just three ports
The company is eligible for 12 months exclusivity from launch
Subscribe To Our Newsletter & Stay Updated
